The pitch sounds almost too convenient: What if you could harness the therapeutic promise of psilocybin—the compound in magic mushrooms—but strip away the hours-long hallucinations that complicate medical use? That question has driven Tampa-based Psilera for the better part of five years, and now the company has closed an $8.8 million Series Seed extension to find out if the science holds up in people.
Psilera announced late last month that it closed an oversubscribed Series Seed extension, bringing total capital raised to more than $11 million. The round, announced May 28, came from a syndicate of institutional and strategic backers the company declined to name—a familiar refrain in biotech, where early investors often prefer to stay out of the spotlight until clinical data arrive.
The fresh capital sets up first-in-human trials in 2027 for PSIL-006, Psilera's lead candidate: a chemically modified psilocybin derivative engineered to promote neural growth without the psychedelic experience. If the molecule works as intended, it could offer a new angle on behavioral variant frontotemporal dementia, a cruel and underserved form of neurodegeneration that erodes personality and impulse control, often before memory fails. There are no approved drugs for it.
Building on Earlier Bets
This extension builds on a $2.5 million seed round Psilera pulled together back in July 2021, when Iter Investments led a group that included Baird Inc., JLS Fund, Receptor, What If Ventures, and company insiders. That earlier money funded the early chemistry and animal studies that eventually produced PSIL-006, which the company unveiled in May 2023.
Since then, Psilera has stitched together a patchwork of non-dilutive funding—the kind of financial engineering that helps biotech founders stretch runway without giving up equity. A National Institutes of Health grant announced in October 2025 is worth up to $2 million over three years and supports a parallel program focused on alcohol use disorder. A February licensing deal with atai Life Sciences, meanwhile, brought roughly $800,000 upfront for Psilera's DMT patent portfolio, according to atai's regulatory disclosures. That transaction effectively allowed Psilera to monetize earlier research while narrowing its focus to psilocybin-derived molecules.
The company did not disclose valuation terms for the latest round, a detail that often signals either founder caution or investor preference to keep pricing quiet ahead of pivotal trials.
The Science (and the Business Case)
Psilera's bet rests on a category of compounds researchers call neuroplastogens—drugs that stimulate the brain's ability to rewire itself, forming new connections and potentially reversing damage from chronic stress, trauma, or neurodegenerative disease. Classic psychedelics like psilocybin fall into this category, but so do synthetic molecules designed to activate the same biological pathways without inducing altered states of consciousness.
PSIL-006 retains activity at the 5-HT2A receptor, the primary target for psilocybin's effects, but Psilera's chemists tweaked the structure to dampen or eliminate the hallucinogenic component. The goal, according to the company, is a drug that patients could take at home and insurers might actually cover—a sharp departure from the model pioneered by companies like Compass Pathways, where psilocybin therapy requires hours of supervised sessions with trained facilitators.
That supervision requirement, however necessary for safety and therapeutic support, complicates the economics. Reimbursement is uncertain, clinics are expensive to operate, and scaling the model to millions of patients seems daunting. A pill you could take daily, by contrast, fits neatly into existing prescription infrastructure.
Whether PSIL-006 actually delivers on that promise is another matter. The company narrowed its lead indication to behavioral variant frontotemporal dementia in January 2024 after preclinical work in animal models suggested the drug might improve behavioral symptoms. FTD, as it's often called, destroys the frontal and temporal lobes, areas that govern personality, judgment, and language. Patients lose empathy, exhibit compulsive behaviors, and often don't recognize they're ill. The disease tends to strike earlier than Alzheimer's—sometimes in people's fifties—and progresses quickly.
The lack of treatments reflects a broader scientific puzzle. While Alzheimer's research has fixated on clearing amyloid plaques (with mixed results), FTD involves a tangle of different protein pathologies and cellular breakdowns. Neuroplasticity-based drugs represent a fundamentally different approach, attempting to rebuild damaged circuits rather than remove toxic proteins. It's an elegant idea. It's also largely unproven in humans.
A Busy Year, and a Delayed Timeline
Psilera has been adding pieces to the puzzle. In January 2026, the company brought on Magali Haas as chief medical officer—a hire that signals preparation for clinical-stage work. Haas spent years at Johnson & Johnson and Cohen Veterans Bioscience, giving her experience navigating both large-pharma bureaucracy and CNS trials, which tend to be long, expensive, and filled with regulatory nuance.
The NIH grant arrived in October, funding toxicology and efficacy studies for an alcohol use disorder candidate—a second indication Psilera has kept in its pipeline. And the atai licensing deal in February cleared the deck financially, letting founders Chris Witowski and Jackie von Salm, both chemistry PhDs from the University of South Florida, focus resources on their psilocybin work.
Still, the timeline has slipped. A February 2025 press release projected first-in-human trials for PSIL-006 starting in 2026. The company now says 2027, a one-year delay it has not publicly explained. In preclinical biotech, such shifts are routine—IND-enabling studies often surface unexpected toxicology issues, manufacturing hiccups, or regulatory feedback that demands additional work. Investors and observers will be watching to see whether further delays materialize.
Psilera plans to present preclinical data at the Oppenheimer CNS Summit on June 10, followed by an appearance at BIO International later that month. Those venues offer a chance to shape the narrative before human trials begin, and perhaps attract partners or crossover investors from the neuroscience world.
A Crowded, Uncertain Field
The neuroplastogen concept has captured attention across the psychedelic-adjacent biotech landscape. Delix Therapeutics, for instance, presented Phase 1b data on zalsupindole—its own non-hallucinogenic compound—at a conference in May, reinforcing the idea that these molecules might work without psychedelic side effects. Academic labs are publishing preclinical studies at a steady clip, and a handful of venture funds have made neuroplastogens a thematic focus.
But enthusiasm hasn't yet translated into approved drugs or definitive human proof-of-concept. The field is still early, still speculative, and still vulnerable to the kind of setbacks that have plagued CNS drug development for decades. Demonstrating efficacy in behavioral symptoms, especially in a disease as heterogeneous and complex as frontotemporal dementia, will require careful trial design and possibly more capital than Psilera has raised to date.
The 2027 trials, assuming they launch on schedule, will offer the first real test. Until then, Psilera remains a promising story built on preclinical science, founder credibility, and a hypothesis that, if it pans out, could reshape how neurologists think about treating neurodegeneration.
Whether the brain will cooperate is, as always, the harder question.
